HRS-5965

DRUG3 trials

Sponsors

Chengdu Suncadia Medicine Co., Ltd.

Conditions

GlomerulonephritisPrimary IgA Nephropathy

Phase 1

Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency

CompletedNCT05505955

Chengdu Suncadia Medicine Co., Ltd.Glomerulonephritis

Start: 2022-10-08End: 2023-11-03Updated: 2024-10-23

Phase 2

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

CompletedNCT06137768

Chengdu Suncadia Medicine Co., Ltd.Primary IgA Nephropathy

Start: 2023-12-19End: 2025-10-17Updated: 2026-07-24

Phase 3

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

RecruitingNCT07014826

Chengdu Suncadia Medicine Co., Ltd.Primary IgA Nephropathy

Start: 2025-06-04End: 2028-12-31Target: 378Updated: 2025-08-05

Related Papers

HRS-5965, a small-molecule factor B inhibitor, in healthy participants and participants with renal insufficiency: A first-in-human, phase 1 trial.

2025-05-151 citations